Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aeglea BioTherapeutics, Inc. (AGLE)

0.4706   -0.03 (-5.9%) 12-05 16:00
Open: 0.5001 Pre. Close: 0.5001
High: 0.5129 Low: 0.464
Volume: 1,836,682 Market Cap: 29(M)

Technical analysis

as of: 2022-12-06 8:15:59 AM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.3     One year: 1.82
Support: Support1: 0.39    Support2: 0.32
Resistance: Resistance1: 1.11    Resistance2: 1.55
Pivot: 1.03
Moving Average: MA(5): 0.6     MA(20): 1.11
MA(100): 0.65     MA(250): 1.7
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 6.3     %D(3): 6.3
RSI: RSI(14): 31.2
52-week: High: 4.82  Low: 0.37
Average Vol(K): 3-Month: 1,908 (K)  10-Days: 3,238 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AGLE ] has closed above bottom band by 10.1%. Bollinger Bands are 277.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.51 - 0.52 0.52 - 0.52
Low: 0.46 - 0.46 0.46 - 0.46
Close: 0.47 - 0.47 0.47 - 0.48

Company Description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Headline News

Mon, 05 Dec 2022
Charu Asopa signs new show - The Tribune India

Mon, 05 Dec 2022
BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201 - Nasdaq

Mon, 05 Dec 2022
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study - Nasdaq

Fri, 02 Dec 2022
Bazaar Agle Hafte: Which Stocks Are On Brokerages Radar? Know Strategy For Mondays Stock Market - Zee Business

Thu, 01 Dec 2022
Is Aeglea Bio Therapeutics Inc (AGLE) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Wed, 30 Nov 2022
Health Care Sector Update for 11/30/2022: AGLE, HZNP, SNY, JNJ, AMGN, CRL, ACER - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 62 (M)
% Held by Insiders 3.556e+007 (%)
% Held by Institutions 2 (%)
Shares Short 683 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.447e+007
EPS Est Next Qtl -0.58
EPS Est This Year -2.07
EPS Est Next Year -2.2
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 482.5
Return on Equity (ttm) -48.8
Qtrly Rev. Growth 5.8e+006
Gross Profit (p.s.) -45.87
Sales Per Share -52.74
EBITDA (p.s.) -2.00681e+007
Qtrly Earnings Growth -1.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -81 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.81

Stock Dividends

Dividend 0
Forward Dividend 611030
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.